June 11 (Reuters) - Novavax Inc said on Friday its COVID-19 vaccine candidate showed immune response and protection against the SARS-CoV-2 Beta variant, which was originally identified in South Africa, in three animal and human studies. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.93 USD | +11.82% | +108.82% | +107.08% |
May. 11 | Wall Street closes up ahead of inflation data | RE |
May. 10 | News Highlights : Top Company News of the Day - Friday at 5 PM ET | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+107.08% | 1.25B | |
+22.13% | 44.96B | |
+0.58% | 42.65B | |
+46.00% | 41.85B | |
-4.27% | 29.04B | |
+10.24% | 26.08B | |
-20.74% | 19.03B | |
+5.35% | 12.75B | |
+27.54% | 12.06B | |
-3.83% | 11.75B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax : says COVID-19 vaccine candidate shows immune response against Beta variant